ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]-

Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]-

Request For Quotation
Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]- Suppliers list
Company Name: Jinan Kabotang Biological Technology Co.,Ltd.  
Tel: 0531-61320525 15866703830
Email: figo.gao@foxmail.com
Company Name: Shanghai Guangyang Carrie Biotechnology Co., LTD  
Tel: 13127532723
Email: lily@yhp-biomedicine.com
Company Name: Shochem(Shanghai)Co.,Ltd  
Tel: +86-021-50800795 13816874662
Email: info@shochem.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: Henan Mengtai Pharmaceutical Technology Co., Ltd  
Tel: 17634413542
Email: 1959525201@qq.com
Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]- Basic information
Product Name:Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]-
Synonyms:Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]-; Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,;Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′;N-((11S,14S)-11-(4-(Dipropylamino)butyl)-1-((S)-7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-14-yl)-15-methyl-7,10,13-trioxo-4-oxa-6,9,12-triazahexadecan-14-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynamide;DL-01
CAS:2821770-49-2
MF:C55H71N9O13S
MW:1098.27
EINECS:
Product Categories:ADC-Linker
Mol File:2821770-49-2.mol
Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]- Structure
Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]- Chemical Properties
density 1.38±0.1 g/cm3(Predicted)
pka11.18±0.20(Predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]- Usage And Synthesis
UsesDL-01 is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs[1].
References[1] Yonghan Hu, et al. Antibody, antibody-drug conjugate thereof and use thereof. Patent WO2023046202A1.
Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]- Preparation Products And Raw materials
Tag:Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]-(2821770-49-2) Related Product Information
NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride Acetamide, 2-amino-N-[[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-14-yl]methyl]- 10H-1,3-Dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-8,11(7H,13H)-dione, 14-(3-aminobicyclo[1.1.1]pent-1-yl)-7-ethyl-7-hydroxy-, (7S)- Glycinamide, N-[6-[2-(methylsulfonyl)-5-pyrimidinyl]-1-oxo-5-hexyn-1-yl]-L-valyl-N6,N6-dipropyl-L-lysyl-N-[[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]propoxy]methyl]- Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT